Netarsudil
Sign in to save this workspacePrimary targets: ROCK1, ROCK2 · FDA status: FDA Approved
Selectivity scorecard
KISS
93.22
Gini
0.676
CATDS
0.012
Computed from wild-type kinome inhibition at 1 μM. Gini reproduces the published values within tolerance; KISS and CATDS are computed but pending reconciliation with the paper's reference code.
Polypharmacology radar
Top 20 strongest-inhibited wild-type kinases for Netarsudil. Strongest target: P70S6K_RPS6KB1 at 99.7% inhibition.
Accessible data table
| Rank | Target | Inhibition % | Residual activity % |
|---|---|---|---|
| 1 | P70S6K_RPS6KB1 | 99.7% | 0.3% |
| 2 | PKCD | 99.4% | 0.6% |
| 3 | ROCK1 | 99.3% | 0.7% |
| 4 | MSK2_RPS6KA4 | 99.1% | 0.9% |
| 5 | PRKX | 98.3% | 1.7% |
| 6 | P70S6KB_RPS6KB2 | 98.2% | 1.8% |
| 7 | PKG1A | 97.3% | 2.7% |
| 8 | PKCEPSILON | 97.3% | 2.7% |
| 9 | PKACB | 97.2% | 2.8% |
| 10 | MSK1_RPS6KA5 | 97.1% | 2.9% |
| 11 | PKCETA | 97.0% | 3.0% |
| 12 | PKA | 96.6% | 3.4% |
| 13 | RSK3 | 96.6% | 3.4% |
| 14 | ROCK2 | 96.0% | 4.0% |
| 15 | STK38_NDR1 | 95.8% | 4.2% |
| 16 | PKG2_PRKG2 | 95.7% | 4.3% |
| 17 | PKACG | 95.4% | 4.6% |
| 18 | STK38L_NDR2 | 95.0% | 5.0% |
| 19 | DMPK2 | 94.8% | 5.2% |
| 20 | PKD2_PRKD2 | 94.6% | 5.4% |
Selectivity landscape
Where Netarsudil sits in the 92-drug selectivity landscape (KISS vs Gini). The highlighted point is Netarsudil.
Annotations
Sign in to read and post annotations.
Loading…